UK - Department of Health and Social Care (DHSC)
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - New Antibiotic for Drug-Resistant Gonorrhoea with GARDP
Programme Data Last Updated: 29/06/2021
IATI Identifier: GB-GOV-10-GAMRIF-WP6-GARDP-2019-2022
The Global Antibiotic Research & Development Partnership (GARDP) is a non-profit product development partnership. It is a research and development initiative addressing global public health needs by developing, delivering and assuring sustainable access of new or improved antibiotic treatments. UK Department of Health and Social Care (DHSC) funding through the Global AMR Innovation Fund (GAMRIF) will support GARDP’s programme on sexually transmitted infections (STI), specifically focusing on the development of a new antibiotic for drug-resistant gonorrhoea.
|Accountable:||UK - Department of Health and Social Care (DHSC)|
|Funding:||UK - Department of Health and Social Care (DHSC)|
|Implementing:||Global Antibiotic Research and Development Partnership|
Sector groups as a percentage of total Programme budget according to the OECD Development Assistance Committee (DAC) classifications.
A comparison across financial years of forecast budget and spend to date on the Programme.